Author

Xuemin Lu

University of Notre DameORCID 0009-0008-0060-8346Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Sharif RahmyiD· 2 shared Xin LüiD· 2 shared Ariana ArceiD· 1 shared Dailin GaniD· 1 shared Guoqiang LiuiD· 1 shared Jing Hui YangiD· 1 shared Jun Li· 1 shared Jun WaniD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Sharif RahmyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintNov 18, 2025

CDH3 as a Novel Therapeutic Target in Basal-like Double-Negative Prostate Cancer

Guoqiang Liu, Shiyu Wang, Loan Duong…·Xin Lü

This study identifies CDH3 as a key driver of basal-like prostate cancer and shows that CDH3-targeted therapies like ADCs and CAR T cells are effective in preclinical models.

DOI 10.1101/2025.11.18.689150

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 7, 2023

Overcome Prostate Cancer Resistance to Immune Checkpoint Therapy with Ketogenic Diet-Induced Epigenetic Reprogramming

Sean Murphy, Sharif Rahmy, Dailin Gan…·Xin Lu

This study shows that combining ketogenic diet and HDAC inhibitors with ICB therapy enhances anti-tumor effects in prostate cancer by modulating epigenetic and immune mechanisms.

DOI 10.1101/2023.08.07.552383

mousescRNA-seq

𝕏 PostBluesky